VIMTALABS Vimta Labs Q1 FY27 results (Apr–Jun 2026) and concall
Vimta Labs delivered a resilient Q1 FY27, achieving 13.7% YoY revenue growth and 16% YoY EBITDA growth. Despite QoQ margin moderation due to specific cost pressures and mixed demand, the company operationalized its Biologics facility with a first order and saw recovery in clinical research. Management expressed confidence in maintaining growth momentum and leveraging strategic initiatives in domestic markets and complex pharma molecules.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 11.2%, net profit up 10.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85 | 90 | 94 | 98 | 102 +20% | 99 +10% | 109 +16% | 109 +11% |
| EBITDA | 30 | 33 | 33 | 34 | 34 +13% | 34 +3% | 39 +18% | 37 +9% |
| Net profit | 15 | 22 | 18 | 19 | 20 +33% | 18 −18% | 21 +17% | 21 +11% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
